Physicians' Academy for Cardiovascular Education

The Imminent danger of Lp(a): Time to face to challenge

Meeting report with video, highlights and slides of an EAS endorsed satellite meeting held prior to the 87th EAS congress in Maastricht, The Netherlands on the imminent danger of Lp(a) - videos will be added soon.

Are we ready for prime-time Lp(a) assay standardization?

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina
Prof. Marcovina emphasizes the importance of considering apo(a) size polymorphism when measuring Lp(a) levels in patients and discusses the Lp(a) Standardization Program.

Lp(a) meeting Prof. Marcovina emphasizes the importance of considering apo(a) size polymorphism when measuring Lp(a) levels in patients and discusses the Lp(a) Standardization Program.

LDL vs Lp(a) cholesterol: confounding

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD
Existing clinical LDL-c assays cannot distinguish LDL-c from Lp(a)-c. Dr. Yeang discusses how Lp(a)-c is included in LDL-c measurements and what the clinical impact of measuring Lp(a)-c can be.

Lp(a) meeting Existing clinical LDL-c assays cannot distinguish LDL-c from Lp(a)-c. Dr. Yeang discusses how Lp(a)-c is included in LDL-c measurements and what the clinical impact of measuring Lp(a)-c can be.

Associations of Lp(a) with CV morbidity and mortality

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD
Pia Kamstrup shares data of two general population studies that reveal the effects of elevated Lp(a) levels on CV events, and effects of Lp(a) risk genotypes, which are consistent with Lp(a) being a causal risk factor for CVD.

Lp(a) meeting Pia Kamstrup shares data of two general population studies that reveal the effects of elevated Lp(a) levels on CV events, and effects of Lp(a) risk genotypes, which are consistent with Lp(a) being a causal risk factor for CVD.

Phase II data on Lp(a) lowering, followed by NHLBI recommendation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas
Prof. Tsimikas discusses the phase 2 apo(a)-LRx trial that evaluated Lp(a) lowering with an antisense oligonucleotide and presents NHLBI recommendations on Lp(a) lowering.

Lp(a) meeting Prof. Tsimikas discusses the phase 2 apo(a)-LRx trial that evaluated Lp(a) lowering with an antisense oligonucleotide and presents NHLBI recommendations on Lp(a) lowering.

Entry of Lp(a) into the CV arena

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Florian Kronenberg, MD
Small isoforms of Lp(a) are associated with high Lp(a) concentrations and increased CVD risk. The team of Kronenberg discovered a mutation in the Kringle-IV type 2 region of Lp(a), which has a modifying effect on Lp(a) levels and CVD risk.

Lp(a) meeting Small isoforms of Lp(a) are associated with high Lp(a) concentrations and increased CVD risk. The team of Kronenberg discovered a mutation in the Kringle-IV type 2 region of Lp(a), which has a modifying effect on Lp(a) levels and CVD risk.

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD
Elisa Waldmann shows prospective data on reduced CV event rates after regular Lp(a) apheresis in patients with high baseline Lp(a) levels and emphasizes the need of randomized controlled data.

Lp(a) meeting Elisa Waldmann shows prospective data on reduced CV event rates after regular Lp(a) apheresis in patients with high baseline Lp(a) levels and emphasizes the need of randomized controlled data.

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD
The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.

Lp(a) meeting The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.

Lp(a) and calcification in aortic stenosis

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Kang He Zheng, MD
Zheng shows study results on the pathophysiological role of elevated Lp(a) and oxidized phospholipids levels in progression of aortic stenosis.

Lp(a) meeting Zheng shows study results on the pathophysiological role of elevated Lp(a) and oxidized phospholipids levels in progression of aortic stenosis.

Slides | Lp(a) and calcification in aortic stenosis

Slides (presentation) - May 29, 2019 - Kang He Zheng, MD - Boston, MA, USA
This lecture by Kang He Zheng was part of the EAS endorsed satellite meeting

Slides as educational service to PACE members and meeting participants

Slides | (Hi)story of Lp(a) into the CV arena

Slides (presentation) - May 24, 2019 - Maastricht, The Netherlands - Florian Kronenberg, MD - Innsbruck, Austria
This lecture by Florian Kronenberg was part of the EAS endorsed satellite meeting

Slides as educational service to PACE members and meeting participants

Slides | Structural determinants of lipoprotein(a) pathogenicity

Slides (presentation) - May 24, 2019 - Maastricht, The Netherlands - Marlys Koschinsky, PhD, FAHA, FNLA - London, ONT, Canada
This lecture by Marlys Koschinsky was part of the EAS endorsed satellite meeting

Slides as educational service to PACE members and meeting participants

Slides | Lp(a) apheresis and CVD risk (modulation)

Slides (presentation) - May 24, 2019 - Maastricht, The Netherlands - Elisa Waldmann, MD - Munich, Germany - EAS endorsed satellite meeting held prior to the 87th EAS congress
This lecture by Elisa Waldmann was part of the EAS endorsed satellite meeting

Slides as educational service to PACE members and meeting participants

The Imminent danger of Lp(a): Time to face to challenge
The Imminent danger of Lp(a): Time to face to challenge